Cimerli

Active Ingredient(s): Ranibizumab-eqrn
FDA Approved: * August 2, 2022
Pharm Company: * COHERUS BIOSCIENCES INC
Category: Vision / Eye Health

Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic[7] that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. Ranibizumab was developed by Genentech and marketed by them in the United States, an... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Related Brands

Drugs with the same active ingredients